Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2)
| Product Name | Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2) |
|---|---|
| Alternate Names | Baricitinib Stable Isotopes, Stable Isotopes of Baricitinib |
| CAT No. | CS-O-36661 |
| CAS No. | 1564241-55-9 |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 375.44 g/mol |
| Mol. For. | C16H13D4N7O2S |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Baricitinib |
| Smileys | N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(C([2H])([2H])C)=O)C1([2H])[2H] |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Baricitinib-D4 (azetidine-2,2-d2)(Ethyl-1,1-d2) is a deuterated form of Baricitinib, a selective and reversible inhibitor of Janus kinase (JAK) 1 and 2. It is used for the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded to other treatments. Baricitinib-D4 works by blocking the activity of JAK1 and JAK2, which are signaling molecules that play a crucial role in the immune system. By blocking these molecules, Baricitinib-D4 helps to reduce inflammation and pain in the joints, improving the overall quality of life of patients with rheumatoid arthritis.
Chemically, Baricitinib-D4 has the molecular formula C16H14D4N7O and a molecular weight of 330.4 g/mol. It is a white to off-white crystalline powder that is soluble in dimethyl sulfoxide, slightly soluble in water, and practically insoluble in ethanol. Baricitinib-D4 is administered orally, with a recommended dose of 4 mg once daily.
Baricitinib-D4 has been extensively studied in clinical trials, and its safety and efficacy have been demonstrated in numerous studies. However, it should be used with caution in patients with a history of tuberculosis, liver or kidney problems, and those who are taking other medications that affect the immune system. Overall, Baricitinib-D4 is a promising treatment option for patients with rheumatoid arthritis who have not responded to other therapies.
Get an Instant Quote
Related Compounds
Baricitinib d5 | Baricitinib D4 (azetidine-2,2,4,4-d4) |